Hypoloc (Nebivolol)

Nebivolol blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. At the same time it stimulates nitric‑oxide release from the endothelium, causing blood‑vessel relaxation. The combined actions lower cardiac output and peripheral resistance, resulting in reduced blood pressure and improved cardiac efficiency.

The exact dose of Hypoloc is determined by the prescribing healthcare professional based on the individual’s medical condition, age, renal function and response to therapy. Physicians typically start with a low dose and may adjust it gradually to achieve the desired blood‑pressure or heart‑failure control.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Hypoloc, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any required import documentation.

Nebivolol is a third‑generation, β1‑selective blocker that also promotes nitric‑oxide‑mediated vasodilation, a property not shared by many older beta‑blockers. This dual mechanism can result in better blood‑pressure control with fewer metabolic side effects, making it a preferred option for patients who need both heart‑rate reduction and vasodilation.

Hypoloc tablets should be stored at ambient temperature, preferably below 25 °C, in their original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Hypoloc is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, split or chew unless specifically instructed by a healthcare professional.

The most serious adverse events include severe bradycardia, marked hypotension, bronchospasm in patients with asthma or COPD, and rare cases of heart block or hepatic injury. Patients should be monitored for symptoms such as faintness, slow pulse, difficulty breathing or jaundice, and seek medical attention promptly if they occur.

Hypoloc is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia (heart rate <60 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure or cardiogenic shock. Caution is also advised for patients with severe asthma, COPD, or significant liver disease.